Massachusetts Financial Services Co. MA decreased its position in Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 3.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 104,766 shares of the biopharmaceutical company’s stock after selling 4,016 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Dynavax Technologies were worth $1,547,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BluePath Capital Management LLC acquired a new stake in shares of Dynavax Technologies during the third quarter worth about $33,000. Advisors Asset Management Inc. lifted its stake in Dynavax Technologies by 498.0% during the 1st quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 1,967 shares during the period. Quantbot Technologies LP increased its stake in shares of Dynavax Technologies by 940.7% in the first quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 2,267 shares during the period. Point72 Middle East FZE purchased a new position in shares of Dynavax Technologies during the fourth quarter worth $53,000. Finally, Metropolitan Life Insurance Co NY lifted its position in Dynavax Technologies by 21.2% during the second quarter. Metropolitan Life Insurance Co NY now owns 7,084 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 1,241 shares during the period. Institutional investors and hedge funds own 99.13% of the company’s stock.
Dynavax Technologies Stock Down 0.8 %
Shares of NASDAQ DVAX opened at $12.82 on Tuesday. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of 32.98 and a beta of 1.26. The company’s 50-day simple moving average is $13.69 and its 200-day simple moving average is $13.95. The company has a quick ratio of 14.49, a current ratio of 15.40 and a debt-to-equity ratio of 0.37. Dynavax Technologies Co. has a 52-week low of $9.42 and a 52-week high of $15.15.
Insiders Place Their Bets
Wall Street Analyst Weigh In
A number of brokerages have issued reports on DVAX. JMP Securities boosted their price target on Dynavax Technologies from $25.00 to $27.00 and gave the company a “market outperform” rating in a report on Friday, November 3rd. The Goldman Sachs Group started coverage on shares of Dynavax Technologies in a report on Thursday, February 1st. They set a “neutral” rating and a $20.00 price target on the stock. Finally, HC Wainwright lifted their price target on Dynavax Technologies from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, November 3rd.
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
- Five stocks we like better than Dynavax Technologies
- Manufacturing Stocks Investing
- 3 attractive stocks that insiders are buying
- What Are Dividend Champions? How to Invest in the Champions
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Upcoming IPO Stock Lockup Period, Explained
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.